To prevent expiration, the United States extended the shelf life of Johnson & Johnson's COVID-19 vaccine.


To prevent expiration, the United States extended the shelf life of Johnson & Johnson's COVID-19 vaccine.

The company stressed that the green light "was based on data from stability evaluation studies" that showed that the single dose is effective "for four and a half months when kept refrigerated at 2 to 8 degrees Celsius."

The US laboratory Johnson & Johnson announced Thursday that the US Food and Drug Administration (FDA) authorized an extension of the shelf life of its COVID-19 vaccine from three months to four and a half months.

The news came when millions of single-dose vaccines stored in refrigerators were at risk of expiring and being discarded. "The decision is based on data from the stability assessment studies that are being carried out," the company said in a statement.

According to the Centers for Disease Control and Prevention (CDC), 21 million doses of the vaccine were distributed throughout the United States, but only 11 million have been administered.

Ohio Gov. Mike DeWine warned this week that 200,000 doses in his state would run out by June 23.

Although not as effective in preventing symptomatic COVID-19 as the messenger RNA vaccines developed by Pfizer and Moderna, J & J's immunizer, based on adenovirus vector technology, was 85% effective in preventing severe forms of the disease. Disease in a significant study.

That figure rose to 100% 28 days after the injection. The fact that the vaccine only required one dose was a key selling point in targeting hard-to-reach populations.

However, acceptance dropped sharply after US authorities suspended the drug for ten days in April for safety reasons.

Authorities believe that the J&J vaccine carries an increased risk of developing a rare but serious type of blood clotting that occurs mostly in women between 18 and 49. This condition, which is caused by a low platelet count, is called vaccine-induced immune thrombocytopenia (TVI).

The United States now has a surplus stock of surplus, highlighting the widening gap between vaccines between rich and poor countries.

President Joe Biden, seeking to regain global leadership on the pandemic, announced Wednesday that the United States would purchase and donate 500 million doses of Pfizer's vaccine for the rest of the world.